ICU admission rates declined for adult CAR-T cell therapy patients at eight U.S. cancer centers between January 2018 and September 2023, according to a study published Dec. 30 in Critical Care Medicine.
Here are three notes from the study:
- ICU admission data was analyzed from eight health systems: New York City-based Memorial Sloan Kettering Cancer Center, Baltimore-based Johns Hopkins University, Houston-based University of Texas MD Anderson Cancer Center, Rochester, Minn.-based Mayo Clinic, Buffalo, N.Y.-based Roswell Park Comprehensive Cancer Center, University of Pittsburgh Medical Center, St. Louis-based Washington University School of Medicine and Cleveland Clinic.
- Between 2018 and 2023, ICU admission rates among CAR-T cell patients declined from 38.5% to 16.4%, while the number of patients treated with CAR-T cells increased annually.
- Compared to 2018, patients admitted to the ICU in 2023 were older, had higher comorbidity indices and more severe toxicities.
Read the full study here.
Leave a Reply